Cardiovascular Research

 
Stock Quotes for Cardiovascular Research top ^
  • Industry: Medical Devices
  • Sector: Healthcare
  • Stock Style: Small Growth
  • Stock Type: Speculative Growth
Sign-up for csii investment picks
  • Industry: Medical Devices
  • Sector: Healthcare
  • Stock Style: Small Growth
  • Stock Type: Speculative Growth
Sign-up for csii investment picks

 
News Articles for Cardiovascular Research top ^
Study Meets Co-Primary Endpoints of LDL Cholesterol Reduction THOUSAND OAKS, Calif.
Sign-up for Amgen Announces Positive Top-Line Results From Phase 3 YUKAWA-2 Trial Of Evolocumab In Combination With Statins In Japanese Patients With High Cardiovascular Risk And High Cholesterol investment picks
RVX-208 Reduces Major Adverse Cardiovascular Events (MACE) Significantly in Patients with Diabetes Mellitus Canada NewsWire In addition, preliminary results from an Australian sponsored trial have yet to verify whether the mechanism of RVX-208 action may affect glucose metabolism.
Sign-up for RVX-208 Reduces Major Adverse Cardiovascular Events (MACE) Significantly in Patients with Diabetes Mellitus investment picks
Philips Furthers Dialogue and Research on Cardiovascular Disease and Sleep Apnea at ESC Congress 2014 Symposium Builds on Philips' Support for SAVE Study Examining Impact of Obstructive Sleep Apnea Treatment on Cardiovascular Disease Canada NewsWire ANDOVER, Mass.
Sign-up for Philips Furthers Dialogue and Research on Cardiovascular Disease and Sleep Apnea at ESC Congress 2014 investment picks
2014/7/23
In addition, preliminary results from an Australian sponsored trial have yet to verify whether the mechanism of RVX-208 action may affect glucose metabolism.
Sign-up for RVX-208 Reduces Major Adverse Cardiovascular Events (MACE) Significantly in Patients with Diabetes Mellitus investment picks
RVX-208 Leads to a 77% Relative Risk Reduction of Major Adverse Cardiovascular Events (MACE) in Patients with Diabetes Mellitus Canada NewsWire Presented in 'State of the Art and Featured Research Session' at the 2014 European Society of Cardiology Congress TSX Exchange Symbol: RVX BARCELONA, Spain and CALGARY, AB , Sept.
Sign-up for RVX-208 Leads to a 77% Relative Risk Reduction of Major Adverse Cardiovascular Events (MACE) in Patients with Diabetes Mellitus investment picks
Symposium Builds on Philips' Support for SAVE Study Examining Impact of Obstructive Sleep Apnea Treatment on Cardiovascular Disease ANDOVER, Mass.
Sign-up for Philips Furthers Dialogue and Research on Cardiovascular Disease and Sleep Apnea at ESC Congress 2014 investment picks
Cardiovascular Systems, Inc. (CSI) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for peripheral and coronary artery disease, today reported financial results for its fiscal fourth quarter and year ended June 30, 2014.
Sign-up for Cardiovascular Systems Reports Fiscal 2014 Fourth-Quarter and Full-Year Financial Results investment picks
Cardiovascular Systems, Inc. (CSI) (NASDAQ:CSII) will host a live webcast of its fiscal 2014 fourth-quarter conference call on Wednesday, August 6, 2014, at 3:45 p.m. CT (4:45 p.m. ET). David Martin, President and Chief Executive Officer, and Larry Betterley, Chief Financial Officer, will discuss the company’s results for its fiscal fourth quarter ended June 30, 2014, and its financial outlook.
Sign-up for Cardiovascular Systems to Webcast Fiscal 2014 Fourth-Quarter Earnings Conference Call Wednesday, August 6 investment picks
2014/8/6
Hologic's Horizon DXA Platform for Osteoporosis, Cardiovascular Disease, and Obesity Assessment Receives Regulatory Approval in Canada Horizon is designed to include the latest in technical capabilities and workflow efficiencies for now and for the future Canada NewsWire BEDFORD, Mass.
Sign-up for Hologic's Horizon DXA Platform for Osteoporosis, Cardiovascular Disease, and Obesity Assessment Receives Regulatory Approval in Canada investment picks
Presented in 'State of the Art and Featured Research Session' at the 2014 European Society of Cardiology Congress TSX Exchange Symbol: RVX BARCELONA, Spain and CALGARY, AB , Sept.
Sign-up for RVX-208 Leads to a 77% Relative Risk Reduction of Major Adverse Cardiovascular Events (MACE) in Patients with Diabetes Mellitus investment picks
Achievement of LDL Particle Targets Associated with More Aggressive Lipid-lowering Therapy and Better Clinical Outcomes Compared to Patients Managed to LDL Cholesterol Targets RALEIGH, N.C. , June 24, 2014 /PRNewswire/ -- LipoScience, Inc. (NASDAQ: LPDX) , today announced the publication of the first large-scale real world study evidencing a link between low LDL-P and reduced cardiovascular disease (CVD) risk.
Sign-up for Study Published in Atherosclerosis Provides First Large-Scale, Real-World Evidence of Link Between Low LDL Particle Levels and Reduced Risk of Cardiovascular Disease investment picks
GARDEN CITY, N.Y. , June 23, 2014 /PRNewswire/ -- Millennium HealthCare Inc. (OTCBB: MHCC) through its wholly owned subsidiary, Millennium Medical Devices, LLC is assisting primary care physicians to offer their patients breakthrough diagnostics that are reimbursable by Medicare and private insurance companies.
Sign-up for Millennium Healthcare Inc. Advances Patient Care With VasoScan Cardiovascular Assessment Test investment picks
PLEASANTON, Calif.
Sign-up for Thoratec Acquires Apica Cardiovascular investment picks
2014/8/13
Taxus Cardium Pharmaceuticals Group Inc. (Trading Symbol: CRXM), today announced the publication of a review article entitled “Identifying and Overcoming Obstacles in Angiogenic Gene Therapy for Myocardial Ischemia,” authored by Gabor M.
Sign-up for Taxus Cardium Announces Biological and Clinical Advances in Angiogenic Gene Therapy for Heart Disease in Journal of Cardiovascular Pharmacology investment picks
2014/8/30
- Study showed significantly more HF-REF patients on LCZ696 regimen were alive, had fewer hospitalizations than those given enalapril regimen(1) - On all-cause mortality, LCZ696 doubled the effect that enalapril, an ACE-inhibitor, previously showed vs.
Sign-up for Novartis' new heart failure medicine LCZ696 cut cardiovascular deaths by 20% vs. ACE-inhibitor in landmark PARADIGM-HF trial investment picks

Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Cardiovascular Research
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Title |  Date |  Author |  Collection |  Interest |  Popularity Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry |  Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry

Previous: Cardinal Health  |  Next: Care Bond Funds